Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review5,7-Dichlorokynurenic acid sodium salt
Description: Potent NMDA antagonist, acts at glycine site; sodium salt of 5,7-Dichlorokynurenic acid
Chemical Name: 5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid sodium salt
Purity: ≥98% (HPLC)
Biological Activity for 5,7-Dichlorokynurenic acid sodium salt
5,7-Dichlorokynurenic acid sodium salt is a sodium salt of 5,7-Dichlorokynurenic acid (Cat. No. 0286), a potent antagonist at the glycine site of the NMDA receptor (Ki = 79 nM vs. [3H]-glycine).
Technical Data for 5,7-Dichlorokynurenic acid sodium salt
| M. Wt | 280.04 |
| Formula | C10H4Cl2NNaO3 |
| Storage | Desiccate at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 1184986-70-6 |
| PubChem ID | 44134672 |
| InChI Key | VPRPMJHKWHCUFW-UHFFFAOYSA-M |
| Smiles | [Na+].OC1=CC(=NC2=CC(Cl)=CC(Cl)=C12)C([O-])=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for 5,7-Dichlorokynurenic acid sodium salt
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| 1eq. NaOH | 28 | 100 |
Preparing Stock Solutions for 5,7-Dichlorokynurenic acid sodium salt
The following data is based on the product molecular weight 280.04. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.57 mL | 17.85 mL | 35.71 mL |
| 5 mM | 0.71 mL | 3.57 mL | 7.14 mL |
| 10 mM | 0.36 mL | 1.79 mL | 3.57 mL |
| 50 mM | 0.07 mL | 0.36 mL | 0.71 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for 5,7-Dichlorokynurenic acid sodium salt
References for 5,7-Dichlorokynurenic acid sodium salt
References are publications that support the biological activity of the product.
Baron et al (1990) Activity of 5,7-dichlorokynurenic acid. A potent antagonist at the NMDA receptor-associated glycine binding site. Mol.Pharmacol. 38 554 PMID: 2172769
Moore et al (1990) Substituted kynurenic acid derivatives. Potent and selective antagonists at the glycine site on the NMDA receptor. Eur.Fed.Med.Chem. (under auspices of IUPAC) XIth I
If you know of a relevant reference for 5,7-Dichlorokynurenic acid sodium salt, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 5,7-Dichlorokynurenic acid sodium salt, 5,7-Dichlorokynurenic acid sodium salt supplier, Potent, NMDA, antagonists, glycine, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, 3698, Tocris Bioscience
2 Citations for 5,7-Dichlorokynurenic acid sodium salt
Citations are publications that use Tocris products. Selected citations for 5,7-Dichlorokynurenic acid sodium salt include:
Rafael et al (2022) GluN3A excitatory glycine receptors control adult cortical and amygdalar circuits. Neuron 110 2438-2454.e8 PMID: 35700736
Lan-Zhen et al (2019) Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell Chem Biol 26 121-130.e5 PMID: 30472117
Do you know of a great paper that uses 5,7-Dichlorokynurenic acid sodium salt from Tocris? Please let us know.
Reviews for 5,7-Dichlorokynurenic acid sodium salt
There are currently no reviews for this product. Be the first to review 5,7-Dichlorokynurenic acid sodium salt and earn rewards!
Have you used 5,7-Dichlorokynurenic acid sodium salt?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.